할로자임 테라퓨틱스(HALO)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $112.45 (+2.53%), 시가총액 $7.58B, PER (주가수익비율) 24.98, 52주 최저~최고 $47.91 ~ $81.23.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED,
할로자임 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
할로자임 테라퓨틱스의 현재 주가는 $112.45 (+2.53%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
할로자임 테라퓨틱스의 시가총액은 약 $7.58B입니다. PER은 24.98입니다.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internation